Product category:
Materials Testing
News Release from: Agilent Technologies Europe | Subject: Microarray platforms
Edited by the Manufacturingtalk Editorial
Team on 20 October 2006
Genome pilot projects use microarray
platforms
The National Cancer Institute (NCI) has announced grant recipients for its coveted Cancer Genome Atlas pilot project, including three institutions using microarray platforms from Agilent Technologies.
The National Cancer Institute (NCI) has announced grant recipients for its coveted Cancer Genome Atlas pilot project, including three institutions using microarray platforms from Agilent Technologies the University of North Carolina, Dana-Farber Cancer Institute and Memorial Sloan-Kettering Cancer centre These prestigious institutions were among seven that were awarded a combined $35 million over three years in NCI grants as Cancer Genome Characterization centres (CGCC) that are designed to implement the Atlas project
This article was originally published on Manufacturingtalk on 23 Jun 2008 at 8.00am (UK)
Related stories
Machine tool calibration accuracy raised
A laser-based calibration system for measuring machine-tool and coordinate-measuring-machine accuracy now has sensors in the system offering accuracy to 0.4ppm.
Non-destructive atomic force microscopy technique
Agilent Technologies has introduced the Magnetic AC Mode III controller that significantly extends atomic force microscopy capabilities.
All three institutions will rely on Agilent's genomics solution, comprising microarrays, reagents, hardware and data analysis tools.
As part of the NCI initiative, each CGCC is expected to process a minimum of 1,000 clinical samples per year.
The CGCC initiative emphasizes high-throughput, high-resolution technologies to detect comprehensively genomic, epigenomic and transcriptome aberrations, including alterations in DNA segment copy numbers, translocations, loss of heterozygosity, altered DNA methylation patterns and changes in gene expression, all of which may play a role in cancer.
Further reading
RNA integrity database for free sharing
Agilent Technologies has announced that its RNA integrity database is now available free of charge online and can eliminate the need to repeat validation experiments.
Lab-instrument qualification service
Agilent Technologies has announced a major addition to its compliance services portfolio: Enterprise Edition.
Informatics software enables discovery of protein
Agilent Technologies has introduced a powerful informatics software solution that enables the rapid discovery of protein and metabolite biomarkers through the analysis of mass spectrometry (MS) data.
The pilot project will explore the benefits of a systematic approach for analyzing specific types and subtypes of tumors.
"The University of North Carolina group, based in the Lineberger Comprehensive Cancer centre, will perform genome-wide gene expression profiling and microRNA expression profiling, both using Agilent DNA oligo microarrays," explained UNC Chapel Hill's Charles M.
Perou, Ph.D., assistant professor, Department of Genetics.
"The UNC group chose the Agilent platform because of its flexibility in gene content, which allows researchers to change any feature, or gene, at any time.
As new genes, microRNAs or gene splice forms are discovered, they can easily and seamlessly be included into the next phase of microarrays.
"The Agilent platform provides proven sensitivity and specificity for each feature," he added, "along with streamlined protocols and hardware that will allow us to achieve the demanding high-throughput needs of the Cancer Genome Atlas project." The Cancer Genome Characterization centre at Harvard Medical School is composed of Raju Kucherlapati, Isaac Kohane, Peter Park and Samuel Aronson of the Harvard Partners centre for Genetics and Genomics; George Church and Jonathan Seidman of the Harvard Medical School; and Lynda Chin, M.D., a researcher with the Dana-Farber Cancer Institute.
"The goal of this centre is to identify novel genes important in initiation and progression of cancer by quantitating DNA and RNA dosage using arrayCGH, or Comparative Genomic Hybridization, and a novel, highly sensitive method called polony sequencing," said Chin.
"We chose CGH as a key tool because genomic alterations have proven to be a productive entry point for discovery of cancer-relevant genes," she added.
"We selected the Agilent platform because of its excellent signal-to-noise detection when hybridized with full-complexity genomic DNA.
We fully expect that future researchers will build on this work, using the same CGH platform." "It is gratifying that Agilent microarrays are playing such a major role in this vital program," said Agilent director of genomics marketing Kevin Meldrum.
"The utility of microarrays has expanded beyond gene expression to applications such as CGH, DNA Methylation, and miRNA.
We're enabling these studies as well as developing our microarray technology by optimizing the balance between density, sensitivity and flexibility with our platform.
It's rewarding to know that these leading researchers and the NCI appreciate the value of this approach." The CGCC program is funded by the NCI and the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health.
• Agilent Technologies Europe: contact details and other news
• Email this article to a colleague
• Register for the free Manufacturingtalk email newsletter
• Manufacturingtalk Home Page
Search the Pro-Talk network of sites
